Breakthrough research shows that stem cell genes can be edited in living systems
New research led by Harvard scientist Amy Wagers has demonstrated that gene-editing machinery can be delivered straight to stem cells where they live, rather than in a dish. Published in Cell Reports, the findings have major implications for biotechnology research and the development of therapeutics for genetic diseases.
“If you want to change a genome to correct a disease-causing gene mutation, you have to change it in the relevant stem cells,” said Wagers, the Forst Family Professor of Stem Cell and Regenerative Biology. “If you don’t change the stem cells, whatever cells you do fix may eventually be replaced with diseased cells fairly quickly. If you do fix the stem cells, they will create healthy cells that can eventually replace the diseased cells.”
But fixing stem cells is harder than it sounds. The way it works now, stem cells have to be extracted, kept alive and healthy, genetically altered, then put back in the patient’s body. The process is disruptive for the cells, which may ultimately be rejected or fail to engraft back into the patient.
Each type of stem cell lives in its own “niche,” well-protected in hard-to-reach areas such as bone marrow. “When you take stem cells out of the body, you take them out of the very complex environment that nourishes and sustains them, and they kind of go into shock,” Wagers said. “Isolating cells changes them. Transplanting cells changes them. Making genetic changes without having to do that would preserve the regulatory interactions of the cells — that’s what we wanted to do.”
Transport by virus
Wagers’ group used an adeno-associated virus (AAV) that infects human (and mouse) cells—but does not cause disease—as a transport vehicle. Building on their earlier work in mice with Duchenne muscular dystrophy, Wagers and her colleagues created various AAV packages to deliver gene-editing cargo into several different types of skin, blood, and muscle stem and progenitor cells.
“This was a true collaboration between labs specializing in several different organs,” said Jill Goldstein, a postdoctoral fellow in the Wagers lab and co-first author of the study. “We set up experiments in our organs of interest, analyzed them, compared notes, and made adjustments in a kind of scientific assembly line. None of us could have done it alone — it takes a lot of hands, and the team approach made it really fun.”
To test whether their AAV complexes managed to deliver, the researchers used mice that act as so-called reporter systems via a “reporter” gene that is normally silenced but can be turned on by gene editing. When the reporter gene is activated, the cell turns bright, fluorescent red.
Up to 60 percent effective
The researchers observed that in skeletal muscle, up to 60 percent of the stem cells turned fluorescent red. In cells that give rise to different types of skin cells, up to 27 percent of the cells turned red. Up to 38 percent of the stem cells in bone marrow (which make blood) were changed. That might seem low, but blood turns over so quickly that in some cases even a single healthy stem cell may be sufficient to rescue a defect.
“So far, the concept of delivering healthy genes to stem cells using AAV hasn’t been practical because these cells divide so quickly in living systems — so the delivered genes will be diluted from the cells rapidly,” said Sharif Tabebordbar, an alumnus of Harvard’s Department of Stem Cell and Regenerative biology and now a postdoctoral fellow at the Broad Institute. “Our study demonstrates that we can permanently modify the genome of stem cells, and therefore their progenies, in their normal anatomical niche. There is a lot of potential to take this approach forward and develop more durable therapies for different forms of genetic diseases. That includes different forms of muscular dystrophy, where tissue regeneration is such an important factor.”
“We looked at the skin of these AAV-transduced mice from the Wagers lab, and were pleased to see that many dermal cells were successfully edited as well,” said Ya-Chieh Hsu, Alvin and Esta Star Associate Professor of Stem Cell and Regenerative Biology. “Those included cells that give rise to dermal adipocytes, and cells that help regulate other stem cells in the skin. We’ve always needed a tool that lets us manipulate dermal cells in vivo rapidly — so for us, this is like a dream come true.”
‘Things might start to move very quickly’
Delivering a gene therapy directly into a living system has been a barrier for biotech companies trying to develop therapies for diseases like spinal muscular atrophy.
“This is a really important resource for the community for two reasons,” Wagers said. “First, it changes the way we can study stem cells in the body. The AAV approach lets researchers investigate the importance of different genes for stem cells in their native environment, much more quickly than ever before. Because the delivery system is so robust, it can also be used to target genes that affect many different tissues.
“Secondly, it’s an important step toward developing effective gene therapies. The approach we developed gets around all the problems you introduce by taking stem cells out of a body and allows you to correct a genome permanently. AAVs are already being used in the clinic for gene therapy, so things might start to move very quickly in this area.”
Learn more: Editing genes at the source
The Latest on: Gene therapy
via Google News
The Latest on: Gene therapy
- Neuro Society at 50 Delves into Mini-Brains, Gene Therapy, Prosthetics and All Else Related to Our Three-Pound Wonderson October 28, 2019 at 2:02 pm
For those who actually were able to make it, a range of topics caught the eye: research on nervous system immune cells implicated in a range of disorders, a gene therapy for converting the brain’s ...
- Gene Therapy/Editing Series 1: A Brief Introduction To Gene Therapyon October 28, 2019 at 9:58 am
This is the first article in a series on gene therapy/editing which was first published on the Marketplace premium service last week. The next article in the premium service will discuss the various ...
- Gene therapy gives Indiana 'miracle' boy 2nd chance at lifeon October 27, 2019 at 3:15 am
When a two-month search for a bone marrow match came up empty, doctors suggested another route. "There was a trial at St. Jude (Children's Hospital) for gene therapy and we were given the option," ...
- Gates Foundation, NIH Bet on Gene Therapy To Bring Cheap HIV and Sickle Cell Cures to Sub-Saharan Africaon October 25, 2019 at 1:00 pm
The National Institutes of Health (NIH) announced a partnership with the Bill and Melinda Gates Foundation on Wednesday to fund the development of targeted cures for HIV and sickle cell disease with a ...
- Rocket’s gene therapy shows long-term efficacy in rare blood disorderon October 25, 2019 at 11:33 am
A gene therapy for a rare blood disorder has shown what the manufacturer calls the first evidence of long-term improvement associated with the disease. New York-based Rocket Pharmaceuticals said ...
- Early Report: Baby Treated With Gene Therapy For Deadly Tay-Sachs Disease Appears To Stabilizeon October 24, 2019 at 11:59 am
But UMass Medical School Dean Terence Flotte this week shared at a conference what could be landmark news about a terrible genetic disease: Two young patients with Tay-Sachs disease showed no ill ...
- PTC Therapeutics Announces Results from Long-Term AADC Deficiency Gene Therapy Treatment Demonstrating Sustained Improvementson October 24, 2019 at 5:00 am
SOUTH PLAINFIELD, N.J., Oct. 24, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. PTCT, +1.20% today announced new results from its investigational gene therapy, PTC-AADC, in patients living with aromatic ...
- Amicus Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 48th Annual Meeting of the Child Neurology Societyon October 24, 2019 at 4:46 am
CRANBURY, N.J., and CHARLOTTE, N.C., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD) today announced additional positive interim results from its CLN6 Batten disease gene therapy program ...
- Can Gene Therapy Cure HIV? US Gov't. Is Banking $100 Million On It.on October 23, 2019 at 10:59 am
Similarly, for sickle cell disease, the goal would be to develop an in vivo therapy that could repair the genetic mutation that causes the disease. This would require a gene-based delivery system that ...
- Sales of Novartis gene therapy approved in May reach $160M for third quarteron October 23, 2019 at 8:20 am
The second gene therapy to win approval in the U.S. saw strong sales in the third quarter of this year, the manufacturer said Tuesday. Basel, Switzerland-based Novartis said in its third-quarter 2019 ...
via Bing News